Eli Lilly, Evidation Health expand collaboration to analyse data from smartphones, sensors

Eli Lilly and Evidation Health have expanded their collaboration with a multi-year agreement to provide the drugmaker with global access to Evidation's Andromeda data platform to analyse large scale data aimed at uncovering novel digital measures of health, the companies announced Friday. As a result of the expansion, Eli Lilly researchers will have access to data derived from smartphones, connected sensors, wearables and the users' voices.

Christine Lemke, co-founder of Evidation, remarked that "our initial collaborations with Lilly demonstrated that digital biomarkers can play a significant role in understanding individuals and disease, and we are excited to expand our collaboration." Lemke added that "the data platform product embodies an industry-wide change to the way we measure health, which makes it more proactive, objective, and ultimately meaningful to individuals." Eli Lilly's chief digital officer, Divakar Ramakrishnan, , remarked that "by leveraging Evidation's Andromeda platform, Lilly's scientists are gaining a deeper understanding of the physiological, environmental, and contextual indicators that can help shape future advancements in medicine and medicine delivery."

Under the agreement, of which financial terms were not disclosed, Eli Lilly scientists will have "instant access to a private, collaborative, and secure analytical environment" where they can use Evidation-built algorithms to process raw data for use in clinical trials or to create their own predictive models. The companies said that "the models turn complex, patient-generated behaviour data into novel, quantifiable and clinically meaningful insights that can transform how diseases are identified, treated and monitored." 

The companies further noted that Evidation's data platform is being used by Eli Lilly to analyse data from continuous glucose monitors, insulin pumps and real world information in order to build a connected ecosystem that includes an automated insulin delivery device and connected insulin pen.

In 2017, Eli Lilly teamed-up with Dexcom to include the latter's continuous glucose monitoring (CGM) into Eli Lilly's Connected Diabetes Ecosystem. The companies said at the time they expected to combine Eli Lilly's smart insulin delivery devices and Dexcom CGM to improve the future of diabetes management. 

Did you like this article?